

AMENDMENT TRANSMITTAL LETTER				DOCKET NUMBER: P-LJ 3430	
SERIAL NO: 09/228,866	FILING DATE: January 12, 1999	EXAMINER: S. Turner	GROUP ART UNIT: 1644		
INVENTION: MOLECULES THAT HOME TO A SELECTED ORGAN IN VIVO					

Attention Box RCE
TO COMMISSIONER FOR PATENTS



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Attention Box RCE, Washington, D.C., 20231 on July 14, 2000.

By: Andrea K. Gashler
Andrea L. Gashler, Reg. No.: 41,029

July 14, 2000
Date of Signature

Transmitted herewith is Response to Office Action mailed February 16, 2000, in the above-identified application.

- Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- Petition for a Two-Month Extension of Time is enclosed (in duplicate).
- Request for Continued Examination is enclosed (in duplicate).
- No additional claims fee is required.
- An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMEND- MENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA CLAIMS PRESENTED	RATE		FEE	
				SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	29	-	29	-	0	x \$9	\$18
INDEPEN- DENT CLAIMS	15	-	12	-	3	x \$39	\$78
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM	<u>YES</u>		<u>X</u> <u>NO</u>	\$130	\$260	= \$0	\$
					TOTAL ADDITIONAL FEE	\$117	\$

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

Please charge my Deposit Account No. 03-0370 the amount of \$. A duplicate copy of this sheet is enclosed.

Inventors: Ruoslahti and Pasqualini
Serial No.: 09/228,866
Filed: January 12, 1999
Page 2 of 2

A check in the amount of **\$652.00** is enclosed, \$117.00 of which covers the small entity additional claims fee, \$345.00 of which covers the fee for the Request for Continued Examination, and \$190.00 of which covers the fee for a two-month extension of time.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.

Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 C.F.R. 1.17.


The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

July 14, 2000

Date

Andrea L. Gashler
Andrea L. Gashler
Registration No. 41,029
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
858-535-9001
USPTO CUSTOMER NO. 23601



PATENT

Our Docket: P-LJ 3430

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Ruosalhti and Pasqualini)
Serial No: 09/228,866)
Filed: January 12, 1999)
For: MOLECULES THAT HOME TO A)
SELECTED ORGAN *IN VIVO*)

Group Art Unit: 1644

Examiner: S. Turner

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Commissioner for
Patents, Attention Box RCE, Washington,
D.C., 20231, on July 14, 2000.

Box RCE
Commissioner for Patents
Washington, D.C. 20231

By Andrea L. Gashler
Andrea L. Gashler, Reg. No. 41,029

July 14, 2000
Date of Signature

RESPONSE TO OFFICE ACTION

Responsive to the Office Action mailed
February 16, 2000, entry of the following amendments and
consideration of the following remarks is respectfully requested.

I. AMENDMENTS

Please amend the claims as follows:

wd 13. (Amended) A conjugate, comprising a peptide that
selectively homes to brain linked to a moiety,

wherein said peptide exhibits at least two-fold greater
specific binding to brain than to kidney and wherein said moiety
is selected from the group consisting of a toxin, drug,
chemotherapeutic agent, cell and liposome.